Exploring the Cost-Reduction Potential of GenAI in Regulatory Medical Writing – Insights from Punya Abbhi
In a recent article published on PharmaTimes, Punya Abbhi, COO of Celegence, explores the transformative potential of Generative AI (GenAI) in reducing the costs associated with regulatory medical writing. This insightful piece delves into the innovative ways GenAI can enhance efficiency and accuracy, offering a forward-looking perspective on the future of regulatory compliance.
Benefits of GenAI in Regulatory Medical Writing
- Cost Reduction: How GenAI can significantly lower the expenses related to regulatory medical writing.
- Efficiency and Accuracy: The role of GenAI in streamlining processes and minimizing errors.
- Future Prospects: The potential long-term impacts of adopting GenAI in regulatory practices.
Read the full article and gain deeper insights into how GenAI can revolutionize regulatory medical writing @PharmaTimes Magazine.
About the Author
Punya Abbhi is the Chief Operating Officer at Celegence, where she spearheads technological innovations such as CAPTIS and Dossplorer to enhance regulatory compliance and efficiency. With extensive experience in the life sciences industry, Punya is a recognized thought leader in leveraging advanced technologies for regulatory excellence.
Celegence’s Expertise
Celegence has proven experience with medical writing for regulatory submissions. Our deep regulatory expertise, combined with advanced AI-Enabled technology solutions, positions us uniquely to handle the complexities of medical writing. We ensure that every document is not only compliant but crafted to expedite approval processes and facilitate market access. For more information about our services or to discuss how GenAI can benefit your regulatory processes, contact us today.
